I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
a study on COVID-19
COVID-19 severe disease Platform Trial Critical Illness TAK-652 Apremilast Icatibant Remdesivir Cenicriviroc Razuprotafib Cenicriviroc (CVC) plus remdesivir Icatibant plus remdesivir Razuprotafib plus remdesivir Apremilast plus remdesivir
Lead Scientists at UCSF
- Carolyn Carolyn, MD
Associate Professor, Family Community Medicine. Authored (or co-authored) 11 research publications. Research interests: HIV primary care · HIV and hepatitis education/training · HIV and hepatitis prevention.
- Kathleen D Liu, MD
EDUCATION College: Harvard University, AB Medical/Graduate School: University of California, San Francisco, MD, PhD RESEARCH My current research areas of interest focus on the predictive and pathogenetic role of biomarkers for both acute and chronic disease states.
- Laura Esserman, MD
Dr. Laura Esserman, M.D., M.B.A is a surgeon and breast cancer oncology specialist practicing at the UCSF Carol Franc Buck Breast Care Center where she has also held the position of Director since 1996. She co-leads the Breast Oncology Program, the largest of the UCSF Helen Diller Comprehensive Cancer Center's multidisciplinary programs.
- accepting new patients
- Start Date
- Completion Date
- QuantumLeap Healthcare Collaborative
- Phase 2
- Study Type
- Last Updated